ASND
Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology · DK
$236.72
−0.97%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- $1.13
- Revenue estimate
- $484.7M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- $3.29
- EPS estimate
- $1.51
- Revenue actual
- $387.5M
- Revenue estimate
- $383.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -245.4%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $315
- PT range
- $273 – $344
- Analysts
- 12
12 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | $1.51 | $3.29 | Beat 117.88% | $387.5M |
| May 7, 2026 | $0.21 | $0.32 | Beat 52.38% | $334.3M |
| Feb 11, 2026 | -$0.06 | -$0.64 | Miss -966.67% | $288.0M |
| Nov 12, 2025 | -$0.41 | -$1.17 | Miss -185.37% | $250.2M |
| Aug 7, 2025 | -$1.42 | -$0.93 | Beat 34.51% | $186.1M |
| May 1, 2025 | -$1.56 | -$1.66 | Miss -6.41% | $110.7M |
| Feb 12, 2025 | -$1.20 | -$0.68 | Beat 43.33% | $180.1M |
| Nov 14, 2024 | -$1.83 | -$1.81 | Beat 1.15% | $63.4M |
| Sep 3, 2024 | -$1.54 | -$2.05 | Miss -33.12% | $38.7M |
| May 2, 2024 | -$1.62 | -$2.48 | Miss -53.33% | $103.0M |
| Feb 7, 2024 | -$2.19 | -$1.66 | Beat 24.14% | $151.4M |
| Aug 16, 2023 | -$3.09 | -$1.54 | Beat 50.19% | $51.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026